Literature DB >> 15877301

Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids.

Qiansha Guo1, Rita Kohen Avramoglu, Khosrow Adeli.   

Abstract

Emerging evidence suggests that overproduction of intestinally derived apolipoprotein (apo) B48-containing lipoprotein particles may be an important contributor to both fasting and postprandial dyslipidemia in insulin-resistant states. Mechanisms regulating the assembly and secretion of apoB48-containing lipoproteins are not fully understood particularly in the diabetic/insulin-resistant intestine. In the present study, we have investigated the density profile of apoB48 lipoproteins assembled in primary hamster enterocytes. Both intracellular and secreted apoB48 particles were examined in intestinal enterocytes isolated from normal or insulin-resistant fructose-fed hamsters, as well as in enterocytes treated with exogenous oleic acid. Microsomal luminal contents and culture media were analyzed by discontinuous and sequential ultracentrifugation on sucrose and KBr gradients, respectively. ApoB48 was mostly secreted on VLDL-, LDL-, and denser HDL-sized particles in the fasting state. In pulse-chase labeling experiments, nascent apoB48-containing particles initially accumulated in the microsomal lumen as HDL-sized particles, with subsequent formation of apoB48-VLDL particles, with only a minute amount of chylomicrons observed. Treatment with 720 mu mol/L of oleic acid, increased microsomal apoB48 HDL synthesis, and induced a marked shift toward lighter more buoyant particles. A marked enhancement in assembly of apoB48-containing lipoproteins was also observed in the microsomal lumen of fructose-fed hamster enterocytes, suggesting facilitated assembly and secretion of dense intestinal lipoprotein particles in insulin-resistant states. Overall, these observations suggest that a major proportion of apoB48-containing lipoprotein particles is assembled and secreted as highly dense, HDL-sized particles. The production of these small, dense, and potentially atherogenic apoB48 particles can be stimulated by increased free fatty acid flux as well as in insulin-resistant diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877301     DOI: 10.1016/j.metabol.2004.12.014

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

Review 1.  Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.

Authors:  Sung Hee Choi; Henry N Ginsberg
Journal:  Trends Endocrinol Metab       Date:  2011-05-26       Impact factor: 12.015

2.  Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance.

Authors:  Mark Naples; Chris Baker; Marsel Lino; Jahangir Iqbal; M Mahmood Hussain; Khosrow Adeli
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-16       Impact factor: 4.052

Review 3.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

4.  Jejunal wall triglyceride concentration of morbidly obese persons is lower in those with type 2 diabetes mellitus.

Authors:  F Soriguer; S García-Serrano; L Garrido-Sánchez; C Gutierrez-Repiso; G Rojo-Martínez; E Garcia-Escobar; J García-Arnés; J L Gallego-Perales; V Delgado; Eduardo García-Fuentes
Journal:  J Lipid Res       Date:  2010-09-20       Impact factor: 5.922

5.  APOB-516 T allele homozygous subjects are unresponsive to dietary changes in a three-month primary intervention study targeted to reduce fat intake.

Authors:  Ahd Hammoud; Marguerite Gastaldi; Matthieu Maillot; Charles S Mercier; Catherine Defoort; Denis Lairon; Richard Planells
Journal:  Genes Nutr       Date:  2009-10-20       Impact factor: 5.523

6.  Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans.

Authors:  Hélène Duez; Benoît Lamarche; René Valéro; Mirjana Pavlic; Spencer Proctor; Changting Xiao; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Circulation       Date:  2008-04-28       Impact factor: 29.690

Review 7.  Inhibition of cholesterol absorption: targeting the intestine.

Authors:  Stephen D Lee; Pavel Gershkovich; Jerald W Darlington; Kishor M Wasan
Journal:  Pharm Res       Date:  2012-08-25       Impact factor: 4.200

8.  Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.

Authors:  Maritza J Romero; Rudolf Lucas; Huijuan Dou; Supriya Sridhar; Istvan Czikora; Eby M Mosieri; Ferenc G Rick; Norman L Block; Subbaramiah Sridhar; David Fulton; Neal L Weintraub; Zsolt Bagi; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

9.  Fructose, insulin resistance, and metabolic dyslipidemia.

Authors:  Heather Basciano; Lisa Federico; Khosrow Adeli
Journal:  Nutr Metab (Lond)       Date:  2005-02-21       Impact factor: 4.169

10.  Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph.

Authors:  Fei Wang; Alison B Kohan; H Henry Dong; Qing Yang; Min Xu; Sarah Huesman; Danwen Lou; David Y Hui; Patrick Tso
Journal:  Physiol Rep       Date:  2014-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.